| Revenue growth | 11.8% YoY for FY26; 13.1% YoY for Q4FY26. |
|---|---|
| Margins | EBITDA margin improved to 15.5% in FY26 (+162 bps). |
| Demand visibility | Softening in some end-user markets due to geopolitical situation. |
| Management confidence | High; citing strategic positioning and diverse product portfolio. |
Growth
FY26: Net Revenue ₹4,211Cr (+11.8% YoY), EBITDA ₹654Cr (+24.5%), PAT ₹293Cr (+26.8%). Q4FY26 PAT surged 35.7%.
Outlook
Demerger implementation scheduled for May 2026; targeting premiumization in spirits and expanding performance chemicals portfolio.
Risks
Geopolitical tensions affecting end-user demand; margin pressure in Ennature Biopharma segment; high raw material costs for seeds.
Earnings Call filed with BSE, NSE: INDIAGLYCO. Summary written with AI assistance from the document.
India Glycols Ltd: key numbers
- Share price
- ₹382.70
- Market cap
- ₹2,565 Cr
- Revenue (annual)
- ₹4,211 Cr
- Net profit (annual)
- ₹292.8 Cr
- P/E (TTM)
- 8.1×Sector 36.8×
- Promoter holding
- 59.63%+0.00% QoQ
- FII holding
- 2.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from India Glycols Ltd
All →India Glycols Board Meeting Outcome
India Glycols Limited announced that its subsidiary, IGL Spirits Limited, approved share allotment under a Scheme of Arrangement and appointed new key managerial personnel.
India Glycols Management Change
India Glycols Ltd announced that four senior management personnel ceased their roles following the effective date of a previously disclosed Scheme of Arrangement.
India Glycols Merger & Restructuring
India Glycols Limited has completed its demerger into three separate entities effective September 1, 2026. The scheme, sanctioned by the NCLT, is now operational.
India Glycols Management Change
India Glycols' subsidiary, Ennature Bio Pharma, announced the appointment of new Directors and a Managing Director. These appointments are part of ongoing corporate updates.
India Glycols Merger & Restructuring
India Glycols Ltd received the certified NCLT order approving the Scheme of Arrangement, which involves the demerger of its Biopharma, Spirits, and Biofuel undertakings.
India Glycols Annual General Meeting
India Glycols held its 42nd Annual General Meeting on August 19, 2026. Shareholders approved all resolutions, including the final dividend payout.